Abstract
COVID-19 has forced life science companies to rapidly adopt a more digital-centric engagement model to support customer engagement and sustain value creation. This has accelerated the need to invest in and optimize digital infrastructure and operating models to support innovative ways of working and evolve traditional sales and marketing strategies in the “new normal.” This study assessed how companies have been impacted by COVID-19 and how they are investing in and implementing digital capabilities and infrastructure in response.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
